Teva Pharma (TEVA) Tops Q2 EPS by 14c; Raises Outlook

Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.78, $0.14 better than the analyst estimate of $0.64. Revenue for the quarter came in at $4.7 billion versus the consensus estimate of $4.74 billion.

GUIDANCE:

Teva Pharma sees FY2018 EPS of $2.55-$2.80, from $2.40-$2.65 and versus the consensus of $2.69. Free cash flow guidance raised to $3.2-3.4 billion from $3.0-3.2 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance
• Universal Logistics Holdings, Inc. (ULH) Tops Q1 EPS by 136c